FDA Commissioner Marty Makary offered his resignation following mounting pressure during his tenure as head of the agency. During a Thursday interview at the FDA’s White Oak Campus in Silver Spring, Maryland, Makary indicated through his demeanor that leadership challenges were mounting. By Tuesday following the interview, he had stepped down. President Trump subsequently praised Makary’s work: “I want to thank Dr. Marty Makary for having done a great job at the FDA. So much was accomplished under his leadership.”
Makary had been selected for the job partly because he was sympathetic to the views of Health and Human Services Secretary Robert F. Kennedy Jr. and the Make America Healthy Again movement. He brought credentials as a pioneering oncologist, surgeon, researcher, and author with advanced degrees from Harvard and Johns Hopkins. During his tenure, Makary emphasized accelerating cures and meaningful treatments by cutting idle time from the regulatory process. He cited the FDA’s rapid approval of a lung cancer drug in 44 days and a deafness treatment approved in record speed as examples of the agency’s capability for urgent action.
The final catalyst for resignation appears to have been disputes over flavored vapes. Makary was reportedly resistant to approving menthol, mango, and blueberry vapes due to concerns they were geared toward underage users. The Trump Administration eventually insisted on FDA authorization, undermining Makary’s position. During his interview, he discussed other regulatory priorities including hormone replacement therapy for menopausal women and the need for randomized-control trials with peptides. Kyle Diamantas was named as acting FDA commissioner.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.menshealth.com/health/a71284292/marty-makary-final-fda-interview/